Price
CHART BY
Frequently asked questions
What is Oric Pharms's market capitalization?
The market capitalization of Oric Pharms is $803.46M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Oric Pharms?
Oric Pharms's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.731. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Oric Pharms's stock?
Currently, 14 analysts cover Oric Pharms's stock, with a consensus target price of $20.92. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Oric Pharms?
Oric Pharms's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$146.82M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Oric Pharms?
Oric Pharms has a free cash flow of -$119.64M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Oric Pharms have, and what sector and industry does it belong to?
Oric Pharms employs approximately 115 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Oric Pharms's shares?
The free float of Oric Pharms is 54.17M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $803.46M
- EPS (TTM)
- -$1.731
- Free Float
- 54.17M
- EBITDA (TTM)
- -$146.82M
- Free Cashflow (TTM)
- -$119.64M
Pricing
- 1D span
- $8.224$8.564
- 52W span
- $3.90$14.76
Analyst Ratings
The price target is $20.92 and the stock is covered by 14 analysts.
Buy
13
Hold
1
Sell
0
Information
Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.
- Employees
- 115
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- ORIC
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet